Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3050970 | 0.90 | MEN1 (0.45) | MEN1KMT2AVCAM1HCAR3ALDH3A1 | |
| SCHEMBL5692011 | 0.81 | MEN1 (0.38) | MEN1KMT2AVCAM1HCAR3ALDH3A1 | |
| SCHEMBL3053986 | 0.80 | MAPT (0.50) | MEN1KMT2AVCAM1HCAR3ALDH3A1 | |
| SCHEMBL3054662 | 0.79 | VCAM1 (0.51) | MEN1KMT2AVCAM1HCAR3ALDH3A1 | |
| SCHEMBL3057297 | 0.78 | PGR (0.44) | MEN1KMT2AMAPTKDM4E | |
| SCHEMBL5692171 | 0.77 | MEN1 (0.36) | MEN1KMT2AHCAR3ALDH3A1MAPT | |
| SCHEMBL3058346 | 0.77 | MEN1 (0.46) | MEN1KMT2AHCAR3ALDH3A1MAPT | |
| SCHEMBL3047731 | 0.76 | VCAM1 (0.48) | VCAM1ALDH3A1MAPTALDH1A1TDP1 | |
| SCHEMBL3055089 | 0.76 | AR (0.49) | — | |
| SCHEMBL3051509 | 0.76 | VCAM1 (0.50) | KMT2AVCAM1MAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148893-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | claimed |
| EP-1654221-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005000795-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-06 | — | — | WO | claimed |
| US-20100222434-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-02 | — | — | US | disclosed |
| EP-2210603-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING THE ACCUMULATION OF AMYLOID- B PROTEIN | Sumitomo Chemical Company, Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20060148893-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | disclosed |
| EP-1654221-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005000795-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222434-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION | APP, PSEN1, BACE1 | MEN1 1465/4885KMT2A 4556/4885VCAM1 2795/4885 |
| US-20060148893-A1 | Chemical compounds | NR3C2, NR5A1, NR3C1 | MEN1 309/4885KMT2A 2581/4885VCAM1 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.